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Abstract
Objective: To evaluate multimodal MRI of the spinal cord in predicting disease progression and one-year clinical status in
amyotrophic lateral sclerosis (ALS) patients.
Materials and Methods: After a first MRI (MRI1), 29 ALS patients were clinically followed during 12 months; 14/29 patients
underwent a second MRI (MRI2) at 1163 months. Cross-sectional area (CSA) that has been shown to be a marker of lower
motor neuron degeneration was measured in cervical and upper thoracic spinal cord from T2-weighted images. Fractional
anisotropy (FA), axial/radial/mean diffusivities (lH, l//, MD) and magnetization transfer ratio (MTR) were measured within
the lateral corticospinal tract in the cervical region. Imaging metrics were compared with clinical scales: Revised ALS
Functional Rating Scale (ALSFRS-R) and manual muscle testing (MMT) score.
Results: At MRI1, CSA correlated significantly (P,0.05) with MMT and arm ALSFRS-R scores. FA correlated significantly with
leg ALFSRS-R scores. One year after MRI1, CSA predicted (P,0.01) arm ALSFSR-R subscore and FA predicted (P,0.01) leg
ALSFRS-R subscore. From MRI1 to MRI2, significant changes (P,0.01) were detected for CSA and MTR. CSA rate of change
(i.e. atrophy) highly correlated (P,0.01) with arm ALSFRS-R and arm MMT subscores rate of change.
Conclusion: Atrophy and DTI metrics predicted ALS disease progression. Cord atrophy was a better biomarker of disease
progression than diffusion and MTR. Our study suggests that multimodal MRI could provide surrogate markers of ALS that
may help monitoring the effect of disease-modifying drugs.
Citation: El Mendili M-M, Cohen-Adad J, Pelegrini-Issac M, Rossignol S, Morizot-Koutlidis R, et al. (2014) Multi-Parametric Spinal Cord MRI as Potential Progression
Marker in Amyotrophic Lateral Sclerosis. PLoS ONE 9(4): e95516. doi:10.1371/journal.pone.0095516
Editor: Cedric Raoul, Inserm, France
Received February 7, 2014; Accepted March 27, 2014; Published April 22, 2014
Copyright:  2014 El Mendili et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the Association Franc¸aise contre les Myopathies (AFM) and the Institut pour la Recherche sur la Moelle e´pinie`re et
l’Ence´phale (IRME). The research leading to these results has also received funding from the program ‘‘Investissements d’avenir’’ ANR-10-IAIHU-06. The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: pierre-francois.pradat@psl.aphp.fr
Introduction
Amyotrophic Lateral Sclerosis (ALS) is the most frequent motor
neuron disease characterized by degeneration of both upper and
lower motor neurons. Disease progression is characterized by
worsening of weakness and physical disability with a median
survival ranging from 2.5 to 3 years [1,2]. There is no curative
treatment and the only available neuroprotective drug is riluzole
that showed only a modest effect on survival but no evidence of
effect on the progression of disability [3]. There is an unmet need
for biomarkers in amyotrophic lateral sclerosis, not only for better
diagnosis but also to assess disease progression and the effect of
disease-modifying drugs in clinical trials (surrogate markers)
[4,5,6]. There is an increasing body of knowledge suggesting that
new neuroimaging approaches, including diffusion tensor imaging
(DTI) and magnetization transfer imaging, may provide promising
biomarkers in ALS [7–10].
MRI studies in ALS mostly investigated neurodegenerative
changes in the brain and thus only investigated upper motor
neuron involvement [11–15]. Spinal cord MRI has the advantage
of investigating the two motor system components that are
involved in ALS, i.e the lower motor neuron (via gray matter
atrophy) and upper motor neuron (via degeneration of corticospi-
nal tract). However, spinal cord imaging has technical limitations
due to the small diameter of the spinal cord, physiological motions
(respiratory and cardiac movements) and susceptibility artifacts
[16,17,18]. Recently, progress in neuroimaging protocols using
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multi-parametric MRI approaches (DTI, MT and atrophy
measurement) allowed to detect abnormalities in the cervical cord
of ALS patients [10,19–22], some metrics being correlated with
upper or lower motor neuron involvement as assessed by
transcranial magnetic stimulation (TMS) results [10]. Two
transversal MRI studies showed a correlation between CSA and
clinical disability [10,22]. For MRI metrics to be used as surrogate
marker of neurodegeneration, longitudinal studies are mandatory
to determine whether these metrics are sensitive to changes over
time and correlate with clinical progression. To address this issue
we performed a spinal cord MRI longitudinal study in a series of
ALS patients.
Materials and Methods
Subjects
Twenty-nine patients with probable or definite ALS were
enrolled in the study and underwent a baseline spinal MRI
examination (MRI1). A follow-up MRI (MRI2) was performed in
14 of these patients after a mean delay of 11.1 months (62.7
months). Follow-up MRI was not feasible in other patients due to
orthopnea (n = 9), worsening of the general condition rendering
transportation and MRI examination impossible (n = 1), loss of
follow-up (n = 2), death (n = 2) and refusal (n = 1). The local Ethics
Committee of our institution approved all experimental proce-
dures (Paris-Ile de France Ethical Committee under the 2009-
A00291–56 registration number), and written informed consent
was obtained from each participant. All clinical investigations have
been conducted according to the principles expressed in the
Declaration of Helsinki.
Revised ALS Functional Rating Scale [23] data were obtained
at MRI1, one year after MRI1 in all 29 ALS patients and at MRI2
for the 14 ALS patients. We calculated an arm ALSFRS-R
subscore pertaining to functions such as handwriting, cutting food
and handling utensils, and a leg ALSFRS-R subscore (walking,
climbing stairs). The patients were also scored on manual muscle
testing (MMT) using the Medical Research Council score [24].
MMT was performed at baseline in all ALS patients and at one
year in the subgroup of patients who had a second MRI. Seven
muscles in each limb were assessed. Information about patients’
demographics and clinical disability are given in Table 1. It
includes disease duration, which was defined as the delay between
the onset of weakness and MRI examination. Patients were scored
on the day of each MRI.
MRI Acquisition
Acquisitions were performed using a 3T MRI system (TIM
Trio, Siemens Healthcare, Erlangen, Germany), with a body coil
for signal excitation and a neck/spine coil for signal reception.
Anatomical imaging was performed at the cervical and upper
thoracic levels. DTI and magnetization transfer imaging were
performed from vertebral C2 to T2 using the following protocol:
Anatomical data. A sagittal T2-weighted three-dimensional
(3D) turbo spin echo (TSE) image with slab selective excitation was
acquired. Imaging parameters were: isotropic voxel size 0.9 mm3;
FOV = 2806280 mm2; 52 sagittal slices; TR = 1500 ms;
TE = 120 ms; acceleration factor = 3; acquisition time , 6 min.
Diffusion weighted-imaging. DTI data were acquired
using a single shot EPI sequence with monopolar diffusion-
weighting scheme. The acquisition was cardiac-gated. Eight axial
slices covering C2 to T2 vertebral levels were acquired. Imaging
parameters were: voxel size = 16165 mm3; FOV = 1286128
mm2; TR = 700 ms; TE = 96 ms; acceleration factor = 2; b-
value = 1000 s/mm2; 64 diffusion encoding directions; 4 averages;
acquisition time , 15 min.
Magnetization transfer. 3D gradient echo images with slab-
selective excitation were acquired with and without magnetization
transfer (MT) saturation pulse (Gaussian envelope, duration
Table 1. Patients demographics and clinical features in the whole population and in the subgroup of patients who had a second
MRI (mean 6 SD).
At baseline At follow up
Characteristics Whole population Sub-group Sub-group Delta Rate of change
Gender 9 Females/20 Males 4 Females/10 Males – – –
Age 53.169.8 years 52.6611 years 53.5611 years – –
Recruitment period Feb 2010– Feb 2011 Feb 2010– Feb 2011 Jun 2011– Jul 2012 – –
Disease duration 26.8626.9 months 28.7627.6 months 39.8628.8 months 11.162.7 months –
Site of onset 16 Upper; 11 Lower; 6 Upper; 8 Lower – – –
2 Upper+Lower
ALSFRS
Arm (/8) 5.0062.25 5.7162.30 2.9362.89 248.75% 20.25 units/month
Leg (/8) 4.7262.47 4.9362.23 3.5062.71 228.99% 20.12 units/month
Total (/48) 37.1466.35 39.9366.18 30.5769.40 221.47% 20.76 units/month
MMT
Arm (/70) 52.90611.90 56.79611.11 45616.44 222.14% 21.06 units/month
Leg (/70) 59.72617.85 61.14616.94 53.79617.13 212.03% 20.58 units/month
Total (140) 112.62623.80 117.93618.29 98.00624.95 216.90% 21.64 units/month
TMS
Threshold (ms) 68.01620.82 63.65618.46 – – –
Amplitude (mV) 1.9261.38 1.6360.97 – – –
doi:10.1371/journal.pone.0095516.t001
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9984 ms, frequency offset 1200 Hz). Imaging parameters were:
voxel size = 0.960.962 mm3; FOV = 2306230 mm2; axial orien-
tation with 52 slices (covering the same C2-T2 region as the DTI
scans), TR = 28 ms; TE = 3.2 ms; acquisition time ,5 min per
volume.
For an exhaustive description of the MRI acquisition param-
eters, the reader is referred to [25].
TMS Examination
TMS was performed within two weeks of the MRI1 using a
MAGSTIM 200 device, delivering monophasic stimulation
through a round coil (9 cm diameter). Responses of hand muscle
(adductor digiti minimi) were recorded with surface electrodes
using a KPnet system (Natus/Dantec, Denmark). The stimulation
was first applied at the cervical level (C7-D1) to excite the root
near its exit from the spinal cord [26]. The motor evoked potential
amplitude was measured to assess lower motor neurons impair-
ment. The motor evoked potential threshold was measured to
assess CST degeneration [27] (Table 1).
DATA Processing
Cord atrophy. Cord cross-sectional area (CSA) was mea-
sured by an experienced operator on the segmentation technic (i.e.
four years experience) on the T2-TSE images in the middle of
vertebral levels from C2 to T6 using the semi-automatic method
that has been shown to be accurate and with a low inter-observer
variability [28,29,30]. The plane perpendicular to the spinal cord
was resampled to minimize partial volume between spinal cord
and cerebrospinal fluid [31]. To increase reproducibility and
accuracy of the used segmentation method, images were
segmented by an experienced operator on the technic.
DTI. Data were corrected for motion slice-by-slice using FSL
FLIRT [32] with three degrees of freedom (Tx, Ty, Rz). Diffusion
metrics were estimated voxel-wise using FSL DTIFIT: fractional
anisotropy (FA), radial diffusivity (lH), axial diffusivity (l//) and
mean diffusivity (MD).
Magnetization transfer. Gradient echo volumes with and
without magnetization transfer pulse were coregistered using FSL
FNIRT non-linear algorithm. Magnetization transfer ratio (MTR)
was computed voxel-wise following the equation 100 6 ((S0 2
SMT)/S0), where S0 and SMT represent the signal without and with
the magnetization transfer pulse, respectively.
Figure 1. Regions of interest definition. (A) T2-weighted MRI mid-sagittal slice for an ALS patient. (B,C) T1-weighted data for MTR (B) and mean
diffusion-weighted data for DTI (C). (D,E) Defined anatomical ROIs. ROIs were selected in the dorso-lateral (red) aspect of the spinal cord to include
most of the CST. (F,G) T2-wheighted data before (F) and after (G) cord outlining. A, anterior, I, inferior; L, left; R, right; P, posterior; S, Superior.
doi:10.1371/journal.pone.0095516.g001
Table 2. Results of stepwise linear regressions.
ALSFRS-R MMT
Predictors Arm Leg Total Arm Leg Total
FA 0.7198 0.0003(*) 0.0393(*) 0.7766 0.1280 0.1975
lH 0.6664 0.4428 0.7222 0.5399 0.1439 0.5993
Cord area 0.0493(*) 0.1492 0.4142 0.0193(*) 0.0434(*) 0.8317
Dependent variables were the ALSFRS-R (arm, leg and total scores) and the MMT (arm, leg and total scores) at MRI1. Predictors were gender, age, disease duration, site
of onset, DTI metrics (FA, lH, l//and MD), MTR, CSA, TMS measurements (MEP threshold and amplitude). Significant values are marked with (*). Only significant
predictors are represented here.
doi:10.1371/journal.pone.0095516.t002
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ROI-based analysis. The lateral portion of the cord was
delineated manually and using geometry-based information by an
experienced operator on segmentation. To minimize bias, these
regions of interest (ROIs) were defined on the mean diffusion
weighted images (for DTI analysis) and on the 3D gradient-echo
T1-weighted image (for MT analysis) (Figure 1). This method has
been shown to be sensitive enough to discriminate changes
between sensory (posterior) and motor (lateral) tracks in the
context of ALS [10] and spinal cord injury [25]. For an exhaustive
description of ROIs definition, the reader is referred to [25].
Statistics
Statistical analysis was performed using Matlab (The Math-
works Inc, MA, USA).
Correlations of MRI metrics with clinical disability at
baseline. Stepwise linear regression was used to find the best
predictor of clinical disability at MRI1 in all 29 patients.
Dependent variables were: ALSFRS-R (total, arm subscore and
leg subscore) and MMT. Predictors were: gender, age, site onset,
disease duration, FA, lH, l//, MD, MTR, cross-sectional area,
MEP threshold and amplitude. The probability for a predictor to
enter the stepwise model was based on a Fisher’s test, with a P-
value set to 0.05.
Prediction of clinical disability after one-year follow-
up. Stepwise linear regression was used to find the best predictor
of clinical disability in all 29 ALS patients one year after MRI1.
Dependent variable was: ALSFRS-R (arm, leg and total scores)
after one-year follow-up. Predictors were: gender, age, site onset,
disease duration, FA, lH, l//, MD, MTR, cross-sectional area,
MEP threshold and amplitude measured at baseline. The
probability for a predictor to enter the stepwise model was based
on a Fisher’s test, with a P-value set to 0.05.
Longitudinal MRI Study
Comparisons between baseline and follow-up
MRI. Wilcoxon signed rank test was performed to evaluate
changes in MRI metrics from MRI1 to MRI2. Correlation
between changes in MRI metrics over time and progression of
clinical disability. Spearman’s rank correlation coefficient was used
to investigate correlations between MRI metrics and rate of
change of clinical disability scores, defined as the change of a
variable between MRI1 and MR2 scans, divided by the time
interval between the two scans.
Results
Correlations of MRI Metrics with Clinical Disability at
Baseline
Cord CSA was the only significant predictor associated with the
arm subscore of ALSFRS-R (P= 0.049) and MMT (P= 0.019 for
arm and 0.04 for leg) scales. FA measure in the lateral segment of
the spinal cord was the only predictor of leg subscore (P= 3.1024)
and total score (P= 0.039) of the ALSFRS-R. Results of stepwise
linear regression analysis are summarized in Table 2 (Bonferroni
non corrected, significance level alpha= 0.0056).
Prediction of Clinical Disability after One-year Follow-up
Results of the stepwise linear regression analysis revealed that
the mean spinal cord CSA at MRI1 was the only predictor of the
arm ALSFRS-R subscore (P= 0.013, Table 3). FA measured at
MRI1 was the only predictor of the leg ALSFRS-R subscore
(P= 0.002). FA, lH and CSA measurements predicted the total
ALSFSR-R score (PFA = 2.10
24, PlH= 0.009, PCSA = 0.014). There
was no predictor of the decline of the arm or leg ALSFRS-R
subscores (P.0.05) (Bonferroni non corrected, significance level
alpha= 0.0056).
Table 3. Results of stepwise linear regressions.
ALSFSR-R
Predictors Arm Leg Total
FA 0.5342 0.0022(*) 0.0002(*)
lH 0.6667 0.1377 0,0093(*)
Cord area 0.0129(*) 0.7775 0.0140(*)
Dependent variables were the ALSFRS-R (arm, leg and total scores) one year after MRI1. Predictors were gender, age, disease duration, site of onset, DTI metrics (FA, lH,
l//and MD), MTR, CSA, TMS measurements (MEP threshold and amplitude). Significant values are marked with (*). Only significant predictors are represented here.
doi:10.1371/journal.pone.0095516.t003
Table 4. MRI metrics at baseline and follow-up in ALS patients (mean 6 SD).
MRI metrics Baseline Follow-up P-value Delta Rate of change
FA 0.52360.054 0.51260.048 0.168 – –
lH (610
23 mm2/s) 0.74060.128 0.78261.113 0.127 – –
l// (610
23 mm2/s) 1.74060.117 1.67960.102 0.052 _ –
MD (61023 mm2/s) 1.05160.115 1.08760.098 0.068 _ –
MTR 33.2262.51 30.0063.15 0.0029(*) 29.68% 20.33 units/month
Cord area (mm2) 59.766.7 58.166.9 0.00085(*) 22,73% 20.14 mm2/month
Significant differences are marked with (*).
doi:10.1371/journal.pone.0095516.t004
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Comparisons between Baseline and Follow-up MRI
MRI metrics for MRI1 and MRI2 in ALS patients are indicated
in Table 4.
The cord CSA decreased in all patients, except in one case, by a
mean of 0.14 mm2/month (P= 9.1024). Only one patient did not
show a decrease in spinal cord area (minor increase of 0.04 mm2/
month), within the range of sensitivity of the segmentation method
[30]. Furthermore, this patient had a very long disease duration (9
years) and was clinically stable between the two MRI. MTR
decreased by 0.33 units/month (P= 0.003). Figure 2 shows plots of
CSA and MTR at baseline and follow-up.
No significant change was detected either for FA (P= 0.168), lH
(P = 0.127), l//(P= 0.052) or for MD (P= 0.068) (Bonferroni
corrected, significance level alpha= 0.008).
Figure 2. Comparisons between ALS patients at baseline and follow-up for individual cross-sectional area and MTR in the dorso-
lateral aspect of the spinal cord that includes mostly the corticospinal tract. Group differences were assessed using Wilcoxon signed rank
test. Levels of significance are indicated as: *P,0.01, **P,0.001.
doi:10.1371/journal.pone.0095516.g002
Figure 3. Correlations between cord area rate of change and the ALSFRS-R arm subscore rate of change and MMT arm subscore
rate of change. Correlation coefficients and P-values are derived from Spearman’s correlation.
doi:10.1371/journal.pone.0095516.g003
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Correlation between Changes in MRI Metrics Over Time
and Progression of Clinical Disability
Results of correlations are shown in Figure 3. The atrophy rate
of the spinal cord area (i.e., CSA rate of change) was highly
correlated with worsening in clinical functional status, the
correlations being higher when considering the arm subscore of
the ALSFRS-R (R= 0.702, P= 0.005) and the arm subscore of the
MMT (R= 0.717, P= 0.004). No correlations were detected
between the atrophy rate of change and rates of changes in the
leg subscore of the ALSFRS-R (R= 0.376, P= 0.185), the total
ALSFSR-R (R= 0.481, P= 0.084), and the leg subscores of the
MMT (R= 0.153, P= 0.601).
No correlations were detected between the rate of change in
MTR and the rates of changes in the arm ALSFRS-R
(R= 0.037, P= 0.914), leg ALSFRS-R (R=20.432, P= 0.184),
arm MMT (R=20.059, P= 0.863) and leg MMT (R= 0.009,
P= 0.979) subscores (Bonferroni corrected, significance level
alpha= 0.025).
Discussion
Results show that spinal cord atrophy and MTR are sensitive
the progression of the tissue neurodegenerative process in the
spinal cord in ALS patients. The cord area at baseline was
predictive of the functional ability of the arms after a one-year
follow-up duration. Between MRI1 and MRI2, MTR decreased
significantly in the lateral segments of the spinal cord by 0.33
units/month and the cross sectional area decreased significantly by
0.14 mm2/month. Furthermore, the atrophy rate of change was
strongly correlated with the rates of change in the arm ALSFRS-R
and MMT subscores.
Significant decrease in cord area in ALS patients followed
longitudinally was previously reported [20], although no correla-
tion with the ALSFRS score was found. Several factors may
explain this lack of correlation in the study of Agosta et al. First,
the lower field strength (1.5T versus 3T) might have been
associated with lower resolution and/or lower signal-to-noise ratio,
yielding less precision in delineating the spinal cord. Second, the
present study includes a larger rostro-caudal portion of the spinal
cord, which may have increased the sensitivity to detect motor
neuron degeneration affecting the ALSFRS score. Third, the
follow-up period was shorter (9 versus 11 months in the present
study) and patients showed a slower ALSFRS decline (0.5 versus
0.8 in the present study). Finally, variability in the population
studied, given the small sample sizes, may also account for the
differences. Among our cohort of 29 patients, a follow-up MRI
was only feasible in 14 patients. This relatively high level of drop-
out rate (52%) is common in longitudinal studies in ALS (from
27% to 75%, depending on the duration of the follow-up) [20,33–
39]. The development of respiratory insufficiency responsible for
orthopnea and severe disability are classical limitations for
performing a re-scan in ALS patients.
Our result suggest that changes over time of spinal cord MRI
metric may reflect to some extent the respective contribution of
lower and upper motor neuron degeneration to disability.
Changes of FA measured in the lateral spinal cord containing
mostly the cortico-spinal tract were linked to leg disablity. These
results are reminiscent of clinical observations, since symptoms
due to upper motor neuron degeneration, particularly spasticity,
mainly affect the lower limb. Stiffness in the lower limb, which
is associated with balance and posture impairment, is a major
cause of disability even in ALS patients without noticeable
motor deficit in the lower limbs [40]. In our previous study, we
showed that CSA was correlated with MEP amplitude, that is a
TMS index of lower motor neuron involvement, and not with
MEP threshold, that is a TMS index of upper motor neuron
involvement [10]. So as, the observed correlations between
atrophy rate of change and arm functional sub-scores decline
suggest that lower motor neuron degeneration was the
determinant factor of the arm disability progression. However,
future study using higher resolution enabling separation between
grey and white matter may provide more arguments to support
these assumptions.
It is possible that cord atrophy partly contributed to the
longitudinal decrease in MTR due to partial volume effects with
adjacent CSF and gray matter, which may have lowered the
apparent MTR calculation from averaging effects. However,
several arguments support that partial volume effect minimally
contributed to the detected effect. Firstly, although cord area was
significantly smaller at follow-up, the variation was about 1.6 mm
2,
which corresponds to a change in radius of less than five microns
(using circular approximation of the cord). Given that pixel size is
161 mm2, the partial volume effect resulting from the coarse grid-
based definition of the ROIs–which only encompass 10–15 voxels
over the corticospinal region–dominates in comparison to the
change in cord diameter. In other words, the variability
introduced by the coarse sampling of MRI markers is orders of
magnitude higher than the systematic bias introduced by a small
change in the cord size. Secondly, during delineation of the cord
we opted for a conservative approach, by leaving out pixels that
were at the cord/CSF or white matter/gray matter interfaces.
Although this approach has flaws, this is the currently adopted
approach for quantifying MRI metrics in the spinal cord. Thirdly,
if it were a pure partial volume effect, differences would also be
observed in the diffusion metrics submitted to the same processing
(spatial resolution was almost the same for DTI and MTR).
However, neither significant difference nor trends were observed
for diffusion metrics between baseline and follow-up. Although
previous studies introduced atrophy as a confound for isolating the
effect of a dependent variable [41], it is often a delicate process due
to the high correlation between atrophy and other MRI metrics
(not due to partial volume effects, but due to degenerative
processes).
Conclusion
In conclusion, we demonstrated a significant relationship
between atrophy rate and disease progression in our cohort of
ALS patients. In addition, our results suggest that spinal cord
cross-sectional area and MTR are more reliable markers of
longitudinal neurodegeneration in the spinal cord compared to
DTI metrics such as FA or radial diffusivity. However the
somewhat lower sensitivity of diffusion MRI might be overcome
thanks to the current improvements in hardware, acquisition and
processing techniques. Further longitudinal studies in a larger
population are needed to validate atrophy rate of the spinal cord
as a valid surrogate marker of disease progression in ALS.
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